Rapid SARS-COV-2 Antigen Test Card Self-test
The Rapid SARS-CoV-2 Antigen Test Card cannot be used as the sole basis to diagnose or exclude SARS-CoV-2 infection. Children under 14 years of age should be assisted by an adult. SUMMARY COVID-19 is an acute respiratory infectious disease caused by the SARS-CoV-2 virus. Infected people either with or without symptoms can be a source of infection.
Tags:
Antigen, Rapid, Asrs, 2 antigen, Rapid sars
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
COVID-19 rapid antigen self-tests
www.tga.gov.auCOVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
Australian public assessment report for Linagliptin
www.tga.gov.au• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
Assessment, Report, Public, Australian, Public assessment, Australian public assessment report for linagliptin, Linagliptin
Australian Public Assessment Report for Silodosin
www.tga.gov.auAustralian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...
Assessment, Report, Public, Australian, Ports, Australian public assessment report for silodosin, Silodosin, Public assessment re port
Guidance 18: Impurities in drug substances and …
www.tga.gov.auTherapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date
Drug, Impurities, Substance, Impurities in drug substances and, Impurities in drug substances and drug
Explanatory notes for pharmaceutical manufacturers on the ...
www.tga.gov.auPE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …
Notes, Pharmaceutical, Life, Manufacturers, Explanatory notes, Explanatory, Explanatory notes for pharmaceutical manufacturers
The use of GMDN codes for IVD medical devices in Australia
www.tga.gov.auGlobal Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to
Devices, Medical, Global, Nomenclature, Global medical device nomenclature
COMIRNATY™ COVID-19 VACCINE
www.tga.gov.auDo not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au
AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …
www.tga.gov.auAUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …
Information, Product, Name, Product information, Qualitative, Astrazeneca
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.auThe RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,
Related documents
Listen der SARS-CoV-2-Schnelltests zur Fachanwendung und ...
www.bag.admin.chMEDsan GmbH, MEDsan SARS-CoV-2 Antigen Rapid Test 6 1180 Merlin Biomedical (Xiamen) Co., Ltd., SARS-CoV-2 Antigen Rapid Test Cassette 0 2029 MEXACARE GmbH, MEXACARE COVID-19 Antigen Rapid Test 0 1775 möLab, mö-screen Corona Antigen Test 0 1190 MP Biomedicals, Rapid SARS-CoV-2 Antigen Test Card 15 1481
Antigen, Rapid, Asrs, 2 antigen rapid, 2 antigen, Rapid sars, Rapid antigen
Appendix I: Comparison of PCR, Serology and Antigen Rapid ...
www.moh.gov.sgAppendix I: Comparison of PCR, Serology and Antigen Rapid Tests Aspects Polymerase Chain Reaction (PCR) Antigen Rapid Test Serology Scientific basis Detection of SARS-CoV-2 viral sequences by nucleic acid amplification tests in respiratory tract specimens. Detection of SARS-CoV-2 viral proteins (antigens) in respiratory tract specimens.
Veritor™ System For Rapid Detection of SARS-CoV-2
bdveritor.bd.comThe BD Veritor™ System for Rapid Detection of SARS-CoV-2 is a rapid (approximately 15 minutes) chromatographic digital immunoassay for the direct detection of the presence or absence of SARS-CoV-2 antigens in respiratory specimens taken from patients with signs and symptoms who are suspected of COVD-19. The test is intended for interpretation in
Antigen-detection in the diagnosis of SARS -CoV-2 ...
apps.who.intAntigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance -2- and cohorting of the most infectious cases and their close contacts (16). Patients who present more than 5-7 days after the onset of symptoms are more likely to have lower viral loads, and the likelihood of false negative results
SARS - CoV - 2 (COVID19) Fact Sheet-
www.cdc.govSARS - CoV - 2 (COVID19) Fact Sheet- There are regulatory considerations that must guide the use of POC instruments for SARS-CoV-2 diagnostic purposes. Testing sites operating a POC diagnostic instrument must have a current certificate via the Clinical Laboratory Improvement Amendments of 1988 (CLIA). During the COVID-19 public